Cargando…

PB2090: TREATMENT OUTCOME OF ORBITAL MARGINAL ZONE B CELL LYMPHOMA -- TEN YEARS FOLLOW UP IN A SINGLE INSTITUTION

Detalles Bibliográficos
Autores principales:	Tan, T.-D., Chiou, L.-W., Kau, H.-C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431415/ http://dx.doi.org/10.1097/01.HS9.0000851192.34480.8f

Ejemplares similares

PB2090: SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Kumar, Shaji, et al.
Publicado: (2023)

PB2291: EFFICACY OF SPLENECTOMY IN SPLENIC MARGINAL ZONE LYMPHOMA
por: Yevstakhevych, Yuriy, et al.
Publicado: (2023)

PB2073: LACK OF AGREEMENT ON EVENT-FREE SURVIVAL DEFINITION IN MARGINAL ZONE LYMPHOMA
por: Bommier, C., et al.
Publicado: (2022)

PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
por: Vitolo, Umberto, et al.
Publicado: (2023)

PB2117: TEN-YEAR SINGLE CENTER EXPERIENCE TREATING PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: CAN RADIOTHERAPY BE OMITTED?
por: Goncalves, I. L., et al.
Publicado: (2022)

PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA
por: Silvestre, Antonio Salar, et al.
Publicado: (2023)

PB2050: COMPARISON OF CLINICAL CHARACTERISTICS OF CHILD AND ADULT PATIENTS WITH PNH: ——TEN-YEAR FOLLOW-UP
por: Yang, Hui, et al.
Publicado: (2023)

PB2309: OUTCOMES OF 22 PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: SINGLE INSTITUTE EXPERIENCE
por: Tumyan, Gayane, et al.
Publicado: (2023)

PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY
por: Cho, Seok-Goo, et al.
Publicado: (2023)

PB2271: ANALYSIS OF CLINICAL AND LABORATORY PARAMETERS IN PATIENTS WITH PRIMARY ORBITAL AND ADNEXAL MUCOSSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA- A TWENTY YEARS SINGLE CENTRE EXPERIENCE
por: Smiljanic, Mihailo, et al.
Publicado: (2023)

PB2467: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 39 PATIENTS WITH NON-HODGKIN LYMPHOMA: LONG-TERM FOLLOW-UP IN A SINGLE CENTRE
por: Louar, Fouzia, et al.
Publicado: (2023)

PB2228: PRECISION MEDICINE IN THALASSEMIA: 30-YEAR EXPERIENCE AT SINGLE INSTITUTE FROM SAUDI ARABIA
por: Al Jaouni, S.
Publicado: (2022)

PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-INSTITUTION EXPERIENCE FOCUSING ON DETAILED ASSESSMENT OF TOXICITIES
por: Hirano, Mitsuhito, et al.
Publicado: (2023)

PB2092: PRIMARY BONE DIFFUSE LARGE B CELL LYMPHOMA: A SINGLE CENTER EXPERIENCE
por: Abichou, G., et al.
Publicado: (2022)

PB2336: TREATMENT PATTERN AND OUTCOME IN SYSTEMIC T AND NK CELL LYMPHOMA: AN ASIAN SINGLE CENTER EXPERIENCE
por: Sung, Meng-Ta, et al.
Publicado: (2023)

PB2257: OUTCOME AND PROGNOSTIC FACTORS OF PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA: A SINGLE-CENTER EXPERIENCE
por: Ali, Nesreen, et al.
Publicado: (2023)

PB2373: A SINGLE-CELL ATLAS OF HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA
por: Zhang, Xiaomei, et al.
Publicado: (2023)

PB2101: TREATMENT OF AGGRESSIVE B-CELL LYMPHOMA WITH DA-EPOCH-R, A SINGLE CENTRE EXPERIENCE
por: Dimitraki, E.-K., et al.
Publicado: (2022)

PB2322: MULTIPLE PRIMARY TUMORS IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA: A RETROSPECTIVE SINGLE-CENTER STUDY
por: Sahakyan, Lusine, et al.
Publicado: (2023)

PB2260: FIVE-YEAR SINGLE-CENTER EXPERIENCE IN THE TREATMENT OF ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA WITH ABVD
por: Vukovic, Vojin, et al.
Publicado: (2023)

PB2093: DIFFUSE LARGE B CELL LYMPHOMA IN THE ELDERLY
por: Abichou, G., et al.
Publicado: (2022)

PB2369: PERIPHERAL T CELL LYMPHOMA: EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS
por: Charfi, Maha, et al.
Publicado: (2023)

PB2338: BONE MARROW INVOLVEMENT IN KOREAN PATIENTS WITH LYMPHOMAS: A 21-YEAR LARGE SINGLE-CENTER STUDY: Keywords: Lymphoma, Bone marrow involvement
por: Kim, Min-Sun, et al.
Publicado: (2023)

PB2131: CLINICAL CHARACTERISTICS AND TREATMENTS OUTCOMES OF PRIMARY GASTROINTESTINAL LYMPHOMA:RETROSPECTIVE SINGLE CENTER STUDY FROM MOROCCO
por: Nora, E., et al.
Publicado: (2022)

PB2070: EFFICACY OF RITUXIMAB MAINTENANCE THERAPY IN ADVANCED-STAGE FOLLICULAR LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE STUDY.
por: Amorós, C., et al.
Publicado: (2022)

PB2348: OUTCOME OF VERY ELDERLY DIFFUSE LARGE B CELL LYMPHOMA, SINGLE CENTER EXPERIENCE, RETROSPECTIVE ANALYSIS
por: Kong, Jee Hyun, et al.
Publicado: (2023)

PB2274: REAL-WORLD OUTCOME OF FOLLICULAR LYMPHOMA IN TAIWAN: A MULTICENTER REGISTRY STUDY
por: Ko, Bor-Sheng, et al.
Publicado: (2023)

PB2155: B-CELL NON-HODGKIN’S LYMPHOMAS ASSOCIATED WITH AMYLOIDOSIS
por: Navrátilova, M., et al.
Publicado: (2022)

PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY
por: Kallel, F., et al.
Publicado: (2022)

PB2062: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC FEATURES OF REFRACTORY HODGKIN’S LYMPHOMA.
por: Ben Sghaier, R., et al.
Publicado: (2022)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
por: Ortuzar Pasalodos, A., et al.
Publicado: (2022)

PB2382: EFFECTS OF ANTIFASCIN COMPOUNDS AGAINST LYMPHOMA CELLS IN VITRO
por: María Hurtado López, Ana, et al.
Publicado: (2023)

PB2262: PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKINN LYMPHOMA
por: Zahra, Kmira, et al.
Publicado: (2023)

PB2284: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC ASPECT OF INDOLENT LYMPHOMAS IN TUNISIA
por: Charef, Ons, et al.
Publicado: (2023)

PB1733: LONG-TERM FOLLOW-UP FOR PATIENTS WITH T CELL LYMPHOBLASTIC LYMPHOMA/ ACUTE LYMPHOBLASTIC LEUKEMIA WHO RECEIVED MODIFIED BFM PROTOCOLS
por: Gao, Yan, et al.
Publicado: (2023)

PB2361: DIFFUSE LARGE B-CELL LYMPHOMA IN THE ELDERLY: RETROSPECTIVE ANALYSIS FROM A SINGLE CANCER CENTER IN ALGIERS
por: Faiza, Talbi, et al.
Publicado: (2023)

PB2321: THE EFFECT OF PRE-TREATMENT SERUM KINDLIN-3 ON HODGKIN AND NON-HODGKIN LYMPHOMAS: A SINGLE CENTER EXPERIENCE
por: Keskin, Melike, et al.
Publicado: (2023)

PB2179: RETROSPECTIVE ANALYSIS OF THE EFFICACY AND SAFETY OF RUXOLITINIB IN CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD). A SINGLE-INSTITUTION EXPERIENCE.
por: Muñiz, Ó., et al.
Publicado: (2022)

PB1810: OUTCOME OF ACUTE MYELOID LEUKEMIA RELAPSE AFTER ALLOGENIC STEM CELL TRANSPLANT: A SINGLE INSTITUTION RETROSPECTIVE STUDY
por: Castoldi, C., et al.
Publicado: (2022)

PB2439: EARLIER ENGRAFTMENT WITHOUT INCREASE OF GVHD IN HIGHER DOSE OF CD34+ CELLS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Tan, Tran-Der, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a2fnem4qje68t9tp25v821q7ed